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Abstract Continuous delivery of antiparkinsonian medi-
cation during a perioperative period is desirable to avoid
‘off’-symptom complications in surgical patients with
concomitant Parkinson’s disease (PD). Fourteen PD
patients undergoing surgery under general anesthesia were
switched from oral dopaminergic medication to transder-
mally delivered 24-h rotigotine (median dose 12 mg/24 h)
for the perioperative period. Rotigotine treatment was
considered feasible by patients, their anesthesiologists and
neurologists with good control of PD symptoms and easy
switching and re-switching of PD medication.
Keywords Parkinson’s disease 
Perioperative management  Rotigotine  Surgery 
Transdermal/parenteral therapy
Introduction
Concomitant Parkinson’s disease (PD) is a signiﬁcant
factor for perioperative morbidity in surgical patients
(Mueller et al. 2009). Among other problems, cessation of
oral dopaminergic medication during the perioperative
period may result in a variety of ‘off’-symptoms and
increased peri and postoperative complications (Ga ´lvez-
Jime ´nezandLang2004).Suddenwithdrawalofdopaminergic
medication may also cause parkinsonism–hyperpyrexia
syndrome (Frucht 2004). Alternative routes of adminis-
tration for continuous drug delivery such as nasogastric or
intraduodenal levodopa, intravenous amantadine, or sub-
cutaneous apomorphine are invasive and imply additional
risks of ECG changes and nausea; intravenous amanta-
dine is not available in the United States. Clinical data
to support the safe perioperative use of these compounds
are sparse. A retrospective analysis of data from two
large multicenter trials suggested rotigotine, a non-ergot
dopamine agonist with D3/D2/D1 activity, as a possi-
ble perioperative management option for PD patients
(Korczyn et al. 2007). Rotigotine has been formulated for
transdermal delivery in a 24-h patch, which ensures
continuous drug release and stable plasma concentrations
over a period of 24 h (Braun et al. 2005). This prospec-
tive, open-label, exploratory trial investigated the feasi-
bility of switching PD patients scheduled for surgery
under general anesthesia from their usual PD medication
to rotigotine transdermal patch for the perioperative
period.
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Patients and study design
Fourteen patients with idiopathic PD from six German trial
sites were enrolled in this prospective, open-label, multi-
center trial (NCT00594464) approved by the respective
local institutional review boards and conducted according
to the Declaration of Helsinki and Good Clinical Practice.
Only patients who required PD medication, who were
scheduled for an operation under general anesthesia, and
who had a physical status classiﬁcation according to the
American Society of Anesthesiologists (ASA) (Camporesi
et al. 1991) of stage II or III were included in the trial. All
patients gave written informed consent.
Following a pretreatment visit (eligibility assessment)
and baseline assessments on the day before surgery,
patients received transdermal 24-h rotigotine patches at
approximately 7 p.m. on the evening before surgery,
replacing their regular PD medication(s) (deﬁned as PD
medication taken within 2 days prior to switching). The
last administration of previous PD medication was at noon
of the preoperative day for most PD medications, i.e.,
cabergoline was stopped upon baseline assessment and
the last levodopa-containing preparations were adminis-
tered in the evening of the pre-operative day. Rotigotine
dose determination was at the discretion of the neurologist;
general guidance regarding target doses was given
according to published literature (LeWitt et al. 2007; Giladi
et al. 2007; Poewe et al. 2007; Deutsche Gesellschaft fu ¨r
Neurologie website). After surgery, previous PD medica-
tion was to be resumed in the evening of the operative day;
if required, rotigotine could be applied for up to 2 weeks
following surgery. The trial was completed by a safety
follow-up 2 weeks after discharge from the hospital.
Clinical assessments
Feasibility of switching to rotigotine treatment for the
perioperative period was assessed by anesthesiologists on
the day of surgery, and by neurologists and patients at
safety follow-up using feasibility questionnaires (Table 1).
Rating scales ranged from 1 (I completely agree) to 6 (I do
not agree at all).
Safety [adverse events (AEs), vital signs, 12-lead ECG,
clinical laboratory parameters] was monitored in all
patients throughout the study. Additionally, blood samples
for the determination of rotigotine plasma concentrations
were obtained prior to the removal of the ﬁrst 24-h patches
and analyzed by liquid chromatography with tandem mass
spectrometry. The apparent rotigotine dose is an estimate
of the amount of rotigotine delivered to the skin within
24 h and is calculated as the difference of the initial drug
content in the unused patch and the residual drug amount in
the used patch. Rotigotine was quantiﬁed in the used ﬁrst
24-h patches by a validated method.
The study design did not include collection of Uniﬁed
Parkinson’s Disease Rating Scale (UPDRS) data because it
Table 1 Feasibility of switching to rotigotine treatment during the perioperative period rated by neurologists, anesthesiologists, and patients
(full analysis set; n = 9)
I completely agree I do not agree at all
1 2 34 56
Neurologists
Switch from previous PD medication was easily feasible 8 (88.9%) 0 0 1 (11.1%)
a 00
Re-switch was easily feasible 8 (88.9%) 0 0 0 0 1 (11.1%)
No unexpected PD symptoms perioperatively 7 (77.8%) 2 (22.2%) 0 0 0 0
The patch is a feasible option 8 (88.9%) 1 (11.1%) 0 0 0 0
Anesthesiologists
No unexpected PD symptoms perioperatively 8 (88.9%) 1 (11.1%) 0 0 0 0
Handling of the patch was simple 7 (77.8%) 2 (22.2%) 0 0 0 0
Handling was not time consuming 8 (88.9%) 1 (11.1%) 0 0 0 0
The patch is a feasible option 6 (66.7%) 2 (22.2%) 0 1 (11.1%)
a 00
Patients
Perioperative patch treatment was easily feasible 8 (88.9%) 1 (11.1%) 0 0 0 0
The symptoms of my PD were well controlled 7 (77.8%) 2 (22.2%) 0 0 0 0
In the course of surgery, I felt safe with the PD patch 6 (66.7%) 2 (22.2%) 0 1 (11.1%) 0 0
Data are number of patients (%)
PD Parkinson’s disease
a The same patient was rated ‘4’ by the neurologist and the anesthesiologist
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123was felt that owing to the effect of surgery during the short
study period, no clinically relevant statement about motor
responses upon a change of PD medication was possible.
An estimate is, however, provided by the answers of neu-
rologists and patients to the feasibility questions (‘‘unex-
pected symptoms of PD’’). Owing to the exploratory
character of the study, no formal sample size calculation
was undertaken. Descriptive statistical analysis was per-
formed with the SAS program (SAS Institute, Cary, NC,
USA, version 9.1) using a full analysis set (FAS) patient
population who had valid data for all three feasibility
assessments. For a direct comparison of the substituted PD
medications at doses of equivalent efﬁcacy, all the dosages
were converted to levodopa dosage equivalents according
to the following formula (modiﬁed from Hobson et al.
2002):
Total levodopa equivalents = regular levodopa dose 9
1 ? levodopa continuous release dose 9 0.75 ? ([regular
levodopa dose ? continuous release levodopa dose 9
0.75)] 9 0.25 if taking tolcapone or entacapone) ? pram-
ipexole dose 9 67 ? ropinirole dose 9 16.67 ? pergolide
dose 9 100 ? bromocriptine dose 9 10 ? cabergoline
dose 9 50 ? amantadine dose 9 0.5 ? selegiline dose 9
10 ? rasagiline dose 9 100.
Adverse events were encoded using the Medical
Dictionary for Regulatory Activities version 9.1.
Results
Fourteen patients (7 female/7 male, mean age 68.7 ±
5.9 years, mean Hoehn & Yahr stage 2.5, mean PD duration
8.1 ± 5.6 years) received rotigotine treatment. Table 2 lists
the baseline characteristics for each patient. Surgery was
postponed in two patients; 12 (85.7%) patients underwent
surgery as per protocol, one of them withdrew his consent
postoperatively.
Orthopedic surgery was the most common surgical
procedure (7 patients); others included midfacial tumor
extirpation, bladder extirpation, plastic surgery, pars plana
vitrectomy and cerebral shunt implantation. Most patients
(71.4%) were on more than one PD medication within
2 days prior to switching. Substituted PD medication
included levodopa (13), dopamine agonists (3 pramipexole,
3 ropinirole, 1 cabergoline), amantadine (4), catechol-
O-methyltransferase inhibitors (4), rasagiline (1) and
biperiden (1). The mean levodopa equivalent dose for the
substituted PD medication was 665 ± 359 mg (Table 2).
The majority of patients (64.3%) received rotigotine for
24 h; three patients (21.4%) were exposed for 2 days and
two patients (14.3%) for 5 days. The median rotigotine
dose was 12 mg/24 h (range 2–16 mg/24 h). Rotigotine
doses for each patient are provided in Table 2.
Assessment outcomes
All three feasibility assessments were available for nine
patients (64.3%) who were included in the FAS patient
population. Table 1 lists the questionnaire ratings. The
majority of neurologists (88.9%), anesthesiologists (88.9%)
and all patients (100%) completely agreed (rating of 1) or
agreed (rating of 2) with the statement that rotigotine
transdermal patch presents a feasible option for the peri-
operative management of PD patients. All patients stated
that their PD symptoms were well controlled (rating of 1 or
2) which corresponded to the specialists’ opinion that most
Table 2 Baseline
characteristics of the study
population (n = 14)
BMI body mass index,
PD Parkinson’s disease
Patient Age
(years)
Gender BMI
(kg/m
2)
Hoehn &
Yahr stage
PD
duration
(years)
Substituted PD
medication
(mg levodopa
equivalent dose)
Rotigotine
dose (mg/24 h)
10101 56 Female 25.8 2 3.1 905 16
10102 70 Female 25.7 3 7.0 500 16
10201 76 Male 23.0 2 6.7 370 8
10202 71 Male 27.3 2 2.7 400 8
10203 63 Female 29.1 1 11.9 1,400 14
10204 80 Male 30.9 3 9.3 800 6
10601 68 Female 25.0 3 14.7 775 8
10602 65 Female 27.3 1 2.7 670 12
10603 71 Female 30.5 3 20.7 100 2
10604 67 Male 28.7 4 12.8 1,295 16
10605 65 Male 24.9 4 8.0 700 16
10901 72 Male 24.0 3 0.6 150 6
11101 72 Female 24.1 1 10.2 650 12
11201 66 Male 22.0 3 3.4 600 12
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123patients did not show unexpected perioperative PD symp-
toms. Handling of the patch, switching and re-switching of
PD medication were also rated easily feasible. In case of
further surgery, the majority of the patients (88.9%) would
again choose rotigotine transdermal patch.
Ten patients (71.4%) reported a total of 46 adverse
events (AEs), mostly mild to moderate in intensity. At the
end of the trial, 93% of AEs were listed as recovered; two
AEs were recovered with sequelae (joint dislocation, dys-
esthesia) and one AE (iron deﬁciency) was ongoing. Five
serious adverse events (SAEs) occurred; one was consid-
ered highly probably related to rotigotine treatment (hal-
lucinations as described below), one may have been related
(ventricular asystole as described below) and three were
considered not drug related (mild post-procedural hema-
toma, moderate wound healing disturbance, and severe
joint dislocation). A 72-year-old male on 6 mg/24 h rot-
igotine presented with moderate visual hallucinations
(SAE) and severe nausea after surgery. The rotigotine dose
remained unchanged and he recovered from the halluci-
nations on the same day and from nausea the day after.
A 56-year-old female on 16 mg/24 h rotigotine had a
ventricular asystole (SAE) after surgery which resolved
spontaneously after 12 s without any therapeutic inter-
vention. Rotigotine was withdrawn. The patient had
experienced marked blood loss during surgery, requiring
pharmacological intervention with catecholamines. Clini-
cal chemistry assessed in the hours before the AE revealed
low potassium and hemoglobin values; additionally, a low
central venous pressure was reported. Concomitant medi-
cations at the time of the event were escitalopram oxalate
(10 mg) once daily for depression and esomeprazole
(40 mg) once daily for reﬂux oesophagitis. The patient had
been on daily doses of 4.2 mg pramipexole, 400 mg of a
levodopa/carbidopa/entacapone formulation and 100 mg
levodopa/carbidopa extended release l/c which had been
stopped the evening before surgery and resumed the day
after surgery. Given the patient’s clinical status during
surgery and before the event, an association to rotigotine
treatment seems unlikely but cannot be excluded.
There were no clinically relevant changes for the other
safety parameters. Rotigotine plasma concentrations could
be determined in ten patients (71.4%) and ranged between
0.164 and 4.230 ng/mL. Mean plasma concentrations
(and apparent rotigotine doses) were in the same range as
in previous clinical trials (Schwarz Pharma Ltd 2010;
Gu ¨ldenpfennig et al. 2005).
Discussion
Switching PD patients from oral dopaminergic medication
to rotigotine transdermal patch for the perioperative period
was considered feasible by a majority of neurologists,
anesthesiologists, and their patients in this exploratory
study. Handling of the patch was deemed simple, and
switching and re-switching of PD medication easily feasi-
ble. Patient acceptance was high and, in case of further
surgery, the majority would again choose rotigotine
transdermal patch. Most patients had been on a regimen
comprising at least two antiparkinsonian medications;
apparently, previous polypharmacy did not inﬂuence the
feasibility of switching to the patch.
Rotigotine absorption was not inﬂuenced by surgical
procedures; apparent doses and plasma concentrations were
within the published range (Schwarz Pharma Ltd 2010;
Gu ¨ldenpfennig et al. 2005).
Rotigotine-related adverse events were limited to two
dopaminergic side effects in one patient (severe nausea and
moderate hallucinations) and one ventricular asystole; and
both were classiﬁed as serious. Both the patients recovered
fully. While hallucinations and nausea are dopaminergic
side effects, an association of the cardiac disorder to rot-
igotine seems unlikely. A recent thorough QT/QTc study in
patients with advanced PD demonstrated that rotigotine
application up to doses of 24 mg/24 h did not induce any
QTc interval changes or other ECG abnormalities, indi-
cating that the drug does not affect cardiac repolarization
(Malik et al. 2008).
Considering the likely complications arising from discon-
tinuation of oral dopaminergic PD medication with shorter
half-lives during the perioperative period (Ga ´lvez-Jime ´nez
and Lang 2004;F r u c h t2004) and the practical problems
associated with current alternative parenteral administration
routes, rotigotine transdermal patch may offer a feasible
alternative for perioperative PD management.
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